JP2013540803A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540803A5
JP2013540803A5 JP2013535462A JP2013535462A JP2013540803A5 JP 2013540803 A5 JP2013540803 A5 JP 2013540803A5 JP 2013535462 A JP2013535462 A JP 2013535462A JP 2013535462 A JP2013535462 A JP 2013535462A JP 2013540803 A5 JP2013540803 A5 JP 2013540803A5
Authority
JP
Japan
Prior art keywords
tnf
antagonist
pharmaceutical composition
composition according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013535462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540803A (ja
JP6004494B2 (ja
Filing date
Publication date
Priority claimed from GBGB1018325.9A external-priority patent/GB201018325D0/en
Priority claimed from GBGB1018362.2A external-priority patent/GB201018362D0/en
Priority claimed from GBGB1113718.9A external-priority patent/GB201113718D0/en
Application filed filed Critical
Priority claimed from PCT/EP2011/069147 external-priority patent/WO2012056044A1/en
Publication of JP2013540803A publication Critical patent/JP2013540803A/ja
Publication of JP2013540803A5 publication Critical patent/JP2013540803A5/ja
Application granted granted Critical
Publication of JP6004494B2 publication Critical patent/JP6004494B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013535462A 2010-10-30 2011-10-31 デュピュイトラン病の治療 Active JP6004494B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1018325.9A GB201018325D0 (en) 2010-10-30 2010-10-30 Treatment for dupuytren's disease
GB1018325.9 2010-10-30
GBGB1018362.2A GB201018362D0 (en) 2010-11-01 2010-11-01 Treatment of dupuytren's disease
GB1018362.2 2010-11-01
GBGB1113718.9A GB201113718D0 (en) 2011-08-10 2011-08-10 Treatment of Dupuytren's Disease
GB1113718.9 2011-08-10
PCT/EP2011/069147 WO2012056044A1 (en) 2010-10-30 2011-10-31 Treatment for dupuytren's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016166524A Division JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Publications (3)

Publication Number Publication Date
JP2013540803A JP2013540803A (ja) 2013-11-07
JP2013540803A5 true JP2013540803A5 (OSRAM) 2014-12-18
JP6004494B2 JP6004494B2 (ja) 2016-10-12

Family

ID=44913268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013535462A Active JP6004494B2 (ja) 2010-10-30 2011-10-31 デュピュイトラン病の治療
JP2016166524A Pending JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016166524A Pending JP2017014266A (ja) 2010-10-30 2016-08-29 デュピュイトラン病の治療

Country Status (9)

Country Link
US (3) US9138458B2 (OSRAM)
EP (1) EP2632446B1 (OSRAM)
JP (2) JP6004494B2 (OSRAM)
AU (2) AU2011322482B2 (OSRAM)
CA (1) CA2847197C (OSRAM)
DK (1) DK2632446T3 (OSRAM)
ES (1) ES2715204T3 (OSRAM)
RU (1) RU2013123796A (OSRAM)
WO (1) WO2012056044A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012056044A1 (en) 2010-10-30 2012-05-03 Imperial Innovations Ltd Treatment for dupuytren's disease
BR112014027347A2 (pt) 2012-05-01 2017-06-27 Proteolease Ltd método para extrair um dente em um sujeito com essa necessidade, método para substituir um dente com um implante dentário e kit para extrair um dente
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
US20160158325A1 (en) * 2013-07-11 2016-06-09 180 Therapeutics Lp Method of treating fibroproliferative disorders including dupuytren's disease with one or more specific human matrix metalloproteinase and a tnf antagonist
AU2016226415B2 (en) * 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
US12344667B2 (en) * 2016-04-08 2025-07-01 180 Therapeutics Lp Method of treating early stage Dupuytren's disease
US20190202907A1 (en) * 2016-09-02 2019-07-04 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
WO2018045210A1 (en) * 2016-09-02 2018-03-08 Therapeutics Lp 180 Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
US11564963B2 (en) 2017-11-22 2023-01-31 Progeneron, Llc Topical compositions, process of large-scale manufacture, and method of use
EP3980022B1 (en) 2019-06-07 2025-01-15 Dale Biotech, LLC Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0939121T4 (da) * 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US6486140B2 (en) 1994-07-19 2002-11-26 Medicarb Ab Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1083337C (zh) 1996-03-26 2002-04-24 精工爱普生株式会社 打印装置及其控制方法
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
GB0105330D0 (en) 2001-03-02 2001-04-18 Renovo Ltd Genetic testing
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002087576A1 (en) * 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
DE60327075D1 (de) 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0306165D0 (en) 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP2007519756A (ja) * 2004-01-30 2007-07-19 アンジオテック インターナショナル アーゲー 拘縮を治療するための組成物および方法
KR20090130158A (ko) * 2005-01-21 2009-12-17 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
AU2010221213B2 (en) 2009-03-06 2014-10-23 Kenneth William Gregg Composition for controlling fish
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
WO2012056044A1 (en) 2010-10-30 2012-05-03 Imperial Innovations Ltd Treatment for dupuytren's disease

Similar Documents

Publication Publication Date Title
JP2013540803A5 (OSRAM)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2009021521A3 (en) Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
MX2012002082A (es) Terapia de acetato de glatiramero de baja frecuencia.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
BR112014006684A2 (pt) análogos de glucagon
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
RU2013123796A (ru) Способ лечения болезни дюпюитрена
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
BR112015010396A2 (pt) terapia de combinação
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NZ606765A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2012007159A3 (en) Novel gastro-retentive dosage forms
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
AR081925A1 (es) Uso de ranolazina para el tratamiento de la hipertension pulmonar
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
MX342020B (es) Apolipoproteina a-iv como un peptido antidiabetico.